HNSBF Quote, Financials, Valuation and Earnings

BioArctic AB has a net margin of -481.29% compared to Hansa Biopharma AB's net margin of -65.15%. Hansa Biopharma AB's return on equity of -- beat BioArctic AB's return on equity of 59.48%.

Hansa Biopharma AB has a consensus price target of --, signalling downside risk potential of --. On the other hand BioArctic AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Hansa Biopharma AB has higher upside potential than BioArctic AB, analysts believe Hansa Biopharma AB is more attractive than BioArctic AB.

Hansa Biopharma AB has a beta of 0.402, which suggesting that the stock is 59.764% less volatile than S&P 500. In comparison BioArctic AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hansa Biopharma AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioArctic AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hansa Biopharma AB pays -- of its earnings as a dividend. BioArctic AB pays out -- of its earnings as a dividend.

Hansa Biopharma AB quarterly revenues are $3.2M, which are smaller than BioArctic AB quarterly revenues of $14M. Hansa Biopharma AB's net income of -$15.6M is lower than BioArctic AB's net income of -$9.1M. Notably, Hansa Biopharma AB's price-to-earnings ratio is -- while BioArctic AB's PE ratio is 32.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hansa Biopharma AB is 12.08x versus 16.63x for BioArctic AB. Usually stocks with elevated PS ratios are considered overvalued.

Camurus AB has a net margin of -481.29% compared to Hansa Biopharma AB's net margin of 33.97%. Hansa Biopharma AB's return on equity of -- beat Camurus AB's return on equity of 21.63%.

Hansa Biopharma AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Camurus AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Hansa Biopharma AB has higher upside potential than Camurus AB, analysts believe Hansa Biopharma AB is more attractive than Camurus AB.

Hansa Biopharma AB has a beta of 0.402, which suggesting that the stock is 59.764% less volatile than S&P 500. In comparison Camurus AB has a beta of 0.933, suggesting its less volatile than the S&P 500 by 6.658%.

Hansa Biopharma AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Camurus AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hansa Biopharma AB pays -- of its earnings as a dividend. Camurus AB pays out -- of its earnings as a dividend.

Hansa Biopharma AB quarterly revenues are $3.2M, which are smaller than Camurus AB quarterly revenues of $59.6M. Hansa Biopharma AB's net income of -$15.6M is lower than Camurus AB's net income of $20.2M. Notably, Hansa Biopharma AB's price-to-earnings ratio is -- while Camurus AB's PE ratio is 53.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hansa Biopharma AB is 12.08x versus 17.95x for Camurus AB. Usually stocks with elevated PS ratios are considered overvalued.

Vivesto AB has a net margin of -481.29% compared to Hansa Biopharma AB's net margin of --. Hansa Biopharma AB's return on equity of -- beat Vivesto AB's return on equity of -23.44%.

Hansa Biopharma AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Vivesto AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Hansa Biopharma AB has higher upside potential than Vivesto AB, analysts believe Hansa Biopharma AB is more attractive than Vivesto AB.

Hansa Biopharma AB has a beta of 0.402, which suggesting that the stock is 59.764% less volatile than S&P 500. In comparison Vivesto AB has a beta of 32.470, suggesting its more volatile than the S&P 500 by 3147.007%.

Hansa Biopharma AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vivesto AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hansa Biopharma AB pays -- of its earnings as a dividend. Vivesto AB pays out -- of its earnings as a dividend.

Hansa Biopharma AB quarterly revenues are $3.2M, which are larger than Vivesto AB quarterly revenues of --. Hansa Biopharma AB's net income of -$15.6M is lower than Vivesto AB's net income of -$755.6K. Notably, Hansa Biopharma AB's price-to-earnings ratio is -- while Vivesto AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hansa Biopharma AB is 12.08x versus -- for Vivesto AB. Usually stocks with elevated PS ratios are considered overvalued.

Orexo AB has a net margin of -481.29% compared to Hansa Biopharma AB's net margin of -33.67%. Hansa Biopharma AB's return on equity of -- beat Orexo AB's return on equity of -134.37%.

Hansa Biopharma AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Orexo AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Hansa Biopharma AB has higher upside potential than Orexo AB, analysts believe Hansa Biopharma AB is more attractive than Orexo AB.

Hansa Biopharma AB has a beta of 0.402, which suggesting that the stock is 59.764% less volatile than S&P 500. In comparison Orexo AB has a beta of 0.861, suggesting its less volatile than the S&P 500 by 13.934%.

Hansa Biopharma AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Orexo AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hansa Biopharma AB pays -- of its earnings as a dividend. Orexo AB pays out -- of its earnings as a dividend.

Hansa Biopharma AB quarterly revenues are $3.2M, which are smaller than Orexo AB quarterly revenues of $12.2M. Hansa Biopharma AB's net income of -$15.6M is lower than Orexo AB's net income of -$4.1M. Notably, Hansa Biopharma AB's price-to-earnings ratio is -- while Orexo AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hansa Biopharma AB is 12.08x versus 1.31x for Orexo AB. Usually stocks with elevated PS ratios are considered overvalued.